Amphastar Pharmaceuticals
As of the edition of 20 October 2026, Amphastar Pharmaceuticals runs 10 drugs, 8 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 3 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 8 |
| Went quiet | 1 |
| Stopped | 1 |
| Total | 10 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Lidocaine | none listed | 2 |
| Epinephrine | none listed | 23 |
| Naloxone | none listed | 10 |
| Furosemide | none listed | 2 |
| Glucagon | none listed | 2 |
| Amiodarone | none listed | 1 |
| Hyaluronidase | none listed | 0 |
| Cosyntropin | none listed | 0 |
A route B row is one company at one target.
Where its trials are
- Immune system: 2 trials led
- Lungs and airways: 2 trials led